Arcutis Biotherapeutics Inc Aktie News

Tori Spelling shares her and her family's journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined – eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherap...

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can be used anywhere on the body for any duration and is not a steroid Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, C...

Arcutis Biotherapeutics delivered strong Q3 results, driven by Zoryve foam's rapid adoption and a shift toward more patent-protected revenue. ARQT achieved earlier-than-expected profitability, established 2026 sales guidance of $455–$470M, and continues expanding Zoryve's label for broader indications. My DCF remodel values ARQT near $25/share, with a reasonable trading range of $15–$39, reflec...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Analyst/Investor Day October 28, 2025 10:30 AM EDT Company Participants Brian Schoelkopf Todd Watanabe - President, CEO & Director Todd Edwards Latha Vairavan - Chief Financial Officer Patrick Burnett - Executive VP & Chief Medical Officer Conference Call Participants Douglas DiRuggiero Presentation Operator Good day, and thank you for standing by. W...

Arcutis Biotherapeutics, Inc. surges after Q3 earnings, driven by strong Zoryve sales and outperformance versus Wall Street expectations. ARQT reported $99.2M in Q3 revenue (up 122% YoY), achieved profitability, and projects 2026 revenues of $455M-$470M with cash flow breakeven. Zoryve's expanding indications, large addressable market, and robust prescription growth support a bullish long-term ...

Management's medium-term sales target for its Zoryve franchise pleased investors. Its near-term sales estimate for 2026 also blasted past analyst estimates.

Arcutis Biotherapeutics smashed quarterly calls Tuesday and reported its first-ever positive net income, leading Arcutis stock to soar.

Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025  ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the treatment of atopic dermatitis in children down to 2 years of age in October  Company provides initial 2026 full year net product sales guidance of $455–$47...